PG 201
Alternative Names: Layla; PG201Latest Information Update: 08 Aug 2019
At a glance
- Originator ViroMed Co Ltd
- Developer PMG Pharm Co Ltd
- Class Antirheumatics; Phytotherapies
- Mechanism of Action Cytokine modulators; Interleukin 1 beta inhibitors; Matrix metalloproteinase inhibitors; Tumour necrosis factor alpha modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteoarthritis
Most Recent Events
- 08 May 2014 PMG initiates enrolment in a phase IV LAYLA_P4_NB trial for Osteoarthritis in South Korea (NCT02049606)
- 01 Sep 2013 PMG Pharm completes a phase IV LAYLA-P4 trial in Osteoarthritis (NCT01768468)
- 01 Dec 2012 Launched for Osteoarthritis in South Korea (PO)